Letter to the Editor

IMPACT OF THE FUNCTIONAL CD5 POLYMORPHISM A471V ON THE RESPONSE OF CHRONIC LYMPHOCYTIC LEUKAEMIA TO CONVENTIONAL CHEMOTHERAPY REGIMENS

Julio Delgado¹, Torsten Bielig², Lizette Bonet², Elena Carnero-Montoro³*, Xose S. Puente⁴, Dolors Colomer⁵, Elena Bosch³, Elias Campo⁵, and Francisco Lozano²,⁶,⁷.

¹Department d’Hematologia, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
²Immunoreceptors del Sistema Innat i Adaptatiu, IDIBAPS, Barcelona, Spain
³Institut de Biologia Evolutiva (UPF-CSIC), Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain
⁴Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
⁵Unitat de Hematopatologia, Departament d’Anatomia Patològica, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
⁶Servei d’Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clinic, Barcelona, Spain
⁷Department de Biologia Cel·lular, Immunologia i Neurociències, Universitat de Barcelona, Barcelona, Spain

Running short title: CD5 variants and CLL prognosis

Key words: chronic lymphocytic leukaemia, CD5 polymorphism, B-cell receptor signalling, B1a lymphocytes, progression-free survival

Address correspondence to: Dr. Francisco Lozano, Centre Esther Koplowitz, Rosselló 149-153, 08036 Barcelona, Spain. Phone: +34-932275400, ext. 4217/4546. Fax: 34-934518038. E-mail: flozano@clinic.ub.es
Chronic lymphocytic leukaemia (CLL) represents an abnormal clonal expansion of mature antigen-experienced CD5+ B1a cells (Chiorazzi et al, 2005), which present with a highly heterogeneous clinical course depending on associated chromosomal aberrations, somatic mutations within the immunoglobulin variable heavy chain genes (IGHV), and surface CD38 or intracytoplasmic ZAP-70 expression. Since key signalling components of the B-cell receptor (BCR) are relevant contributors to the variable clinical behaviour of CLL (Stevenson et al, 2011) we explored the influence of functionally relevant germline CD5 variants on CLL prognosis. The rationale behind this is that CD5, a lymphocyte receptor normally expressed in all T cells and the B1a cell subset, is considered a negative modulator of intracellular signalling mediated by the antigen-specific receptor present on both T (TCR) and B1a (BCR) cells, to which physically associates (Soldevila et al, 2011). Moreover, in both normal and leukemic B cells, CD5 signalling is relevant for production of the B1a cell autocrine growth factor IL-10, and for acquisition of a common gene transcription signature (Gary-Gouy et al, 2007).

The existence of common nonsynonymous CD5 single nucleotide polymorphisms (SNPs) has been recently reported (Carnero-Montoro et al, 2012). Two of them, rs2241002 (C>T) and rs2229177 (C>T), coding for amino acid changes at the extracellular (P224>L) and cytoplasmic (A471>V) regions of CD5, respectively, conform haplotypes relevant to CD5-mediated signal transduction. Accordingly, homozygous carriers of the ancestral P224-A471 (CC) haplotype are less efficient than the more recently derived P224-V471 (CT) haplotype in providing inhibitory signals to TCR-mediated activation responses and are associated with more clinically aggressive forms of autoimmune disease (Cenit et al, 2014). In light of this evidence, the putative influence of CD5 SNPs rs2241002 and rs2229177 on clinical outcome of CLL patients from our Hospital was explored.

In total, 935 patients from our CLL database had DNA samples available for study. Median age was 63 years (range, 18-98 years) at CLL diagnosis. Binet stage was A in 83% of patients, B in 12% of patients, and C in 5% of patients. Results of FISH, CD38 expression, ZAP70 expression and IGHV mutation status were available in 81%, 77%, 83% and 79% of patients. Median follow-up was 34 months (range, 1-158) from frontline therapy and 93 months (range, 1-471) from diagnosis. Four hundred and seventeen (44%) patients required therapy at least once. The most commonly used chemotherapeutic agents were fludarabine, alone or in combination (37%).
chlorambucil (28%), COP/CHOP chemotherapy (17%) and cladribine (6%). Only 10% of these patients received rituximab as frontline therapy. The A471V genotypes CC, CT and TT were observed in 202 (22%), 432 (48%) and 269 (30%) patients, respectively. Regarding P224L, genotypes CC, CT and TT were documented in 575 (63%), 316 (34%) and 29 (3%) patients, respectively. There were no significant differences across all different A471V genotypes in terms of age, sex, prognostic factors, therapy administered or follow-up.

Median PFS from frontline therapy was 46 months (95% confidence interval: 38-52 months) for those patients who required therapy. Known adverse prognostic factors, such as high ZAP-70 expression (P<0.001), unmutated IGHV status (P<0.001), adverse FISH aberrations (P=0.002) and high CD38 expression (P=0.007) had a significant impact on PFS when the entire cohort was analysed. The A471V polymorphism had a trend towards a significant impact on PFS (P=0.052), while P224L had no significant effect on this outcome.

Next, only patients who required therapy but were homozygous for the most prevalent P224L genotype (P224P, CC) were selected for evaluation of the impact of the A471V polymorphism. Baseline characteristics of this selected population of patients are displayed in Table I. Age, sex, prognostic factors, therapy and follow-up were well balanced across all three genotypes. High ZAP-70 (P=0.001) and CD38 expression (P=0.008), and unmutated IGHV status (P<0.001) were equally significant in terms of PFS in this selected population, as was the A471V genotype. Indeed, patients carrying a CC or CT A471V genotype had a significantly prolonged median PFS compared to TT carriers (51 vs. 41 months, P=0.024) (Fig. 1A). This prognostic impact was particularly evident in patients with mutated IGHV (110 vs. 40 months, P=0.028), and not in patients with unmutated IGHV (36 vs. 47 months, P=1.0) (Fig. 1B). A multivariate Cox regression analysis comprising CD38 and ZAP-70 expression, A471V polymorphism and FISH aberrations was performed in this subgroup of patients with mutated IGHV, revealing that both the A471V polymorphism (hazard ratio [HR] = 3.7; 95% confidence interval = 1.21-11.3; P=0.21) and FISH aberrations (HR=3.5; 95% CI=1.08-11.3; P=0.036) had independent prognostic value in terms of PFS.

The overall survival was also analyzed but neither A471V, P224L nor the combined effect had any significant impact on that outcome, although there was a trend towards a significantly longer overall survival for patients carrying a CC or CT genotype for
A471V but only in patients with P224P (CC) genotype and mutated $IGHV$ genes ($P=0.073$).

The present results indicate that CLL patients either homo- or heterozygous for the ancestral $CD5$ allele A471 (C) have significantly prolonged PFS in less aggressive cases presenting mutated $IGHV$. They are reminiscent of a previous single report (Sellick et al, 2008) showing that the more recently derived V471 (T) allele was associated with shorter PFS independently of $IGHV$ mutational status. In our study, this effect was particularly evident when we restricted the analysis to patients with the P224P (CC) genotype and mutated $IGHV$, and non-existent in patients with unmutated $IGHV$. Interestingly, most unmutated $IGHV$ CLL cases contain mutations in driver genes, most of them conferring a bad prognosis and faster progression (Puente et al, 2015). By contrast, most mutated $IGHV$ cases have mutations in better prognosis drivers such as $MYD88$ or del(13q14), resulting in a less aggressive disease. These differences might allow the observation of the protecting effect of $CD5$ polymorphisms only in mutated $IGHV$ cases. On the other hand, only 10% of patients received a rituximab-based regimen, which may or may not abrogate the impact of the polymorphism, and is therefore the main limitation of our study.

How the $CD5$ A471V variants influence the natural behaviour of CLL cells is an unresolved question. However, the lower signal transducing capability of the A471 variant (Carnero-Montoro et al, 2012; Cenit et al, 2014) could result in either 1) a lower capability for negatively modulating the antigen-receptor (BCR) mediated signalling, or 2) a lower anti-apoptotic signalling (Tibaldi et al, 2011). Whatever the case, the present results support the notion that CD5 is not only a phenotypic marker but a relevant player in CLL cell biology as demonstrated by the influence of germline-defined functional $CD5$ variants on CLL outcome.
Acknowledgements
The authors would like to thank all CLL patients who participated in this study and to Marta Consuegra-Fernández for artwork assistance. The work is supported by grants from Worldwide Cancer Research (14-1275), Fundació La Marató TV3 (201319-30), Spanish Ministerio de Economía y Competitividad (Plan Nacional I+D+i, SAF2013-46151-R; and International Cancer Genome Consortium for Chronic Lymphocytic Leukemia, ICGC-CLL) co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, through Instituto de Salud Carlos III (ISCIII); and Red Temática de Investigación del Cáncer (RTICC).

Competing interests
The authors have no competing interests.

Author contributions
All authors were involved in the design and approval of the final manuscript. FL supervised the work and wrote the manuscript. JD analyzed the data and wrote the manuscript. TB, LB, EC-M and EB performed the genetic analyses. XP, DC and EC provided the patient’s samples and clinical data.
REFERENCES


Table I. Baseline characteristics according to the A471V polymorphism of patients who required CLL-specific therapy and had a homozygous P224P (CC) genotype

<table>
<thead>
<tr>
<th>A471V genotype</th>
<th>CC (n = 156)</th>
<th>CT (n = 249)</th>
<th>TT (n = 141)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), median (range)</td>
<td>65 (32-93)</td>
<td>64 (28-98)</td>
<td>63 (18-94)</td>
<td>.855</td>
</tr>
<tr>
<td>Sex, % male/female</td>
<td>58/42</td>
<td>53/47</td>
<td>60/40</td>
<td>.280</td>
</tr>
<tr>
<td>Binet stage B or C, n (%)</td>
<td>26 (17)</td>
<td>40 (16)</td>
<td>14 (10)</td>
<td>.180</td>
</tr>
<tr>
<td>Serum beta2-microglobulin (mg/l), median (range)</td>
<td>1.9 (1.0-33)</td>
<td>2.1 (1.0-17)</td>
<td>2.2 (1.5-11)</td>
<td>.129</td>
</tr>
<tr>
<td>Positive CD38 expression, n (%)</td>
<td>33 (27)</td>
<td>59 (31)</td>
<td>27 (24)</td>
<td>.445</td>
</tr>
<tr>
<td>Positive ZAP70 expression, n (%)</td>
<td>34 (25)</td>
<td>49 (24)</td>
<td>36 (30)</td>
<td>.429</td>
</tr>
<tr>
<td>Unmutated IGHV gene, n (%)</td>
<td>47 (37)</td>
<td>66 (33)</td>
<td>45 (40)</td>
<td>.464</td>
</tr>
</tbody>
</table>

FISH aberrations (Döhner’s hierarchical model):

| Favorable (13q-,+12, none) | 105 (81) | 180 (86) | 96 (83) |
| Unfavorable (11q-, 17p-) | 24 (19) | 29 (14) | 19 (17) |

Frontline therapy:

| Chlorambucil, n (%) | 21 (32) | 29 (28) | 14 (22) |
| CHOP/COP, n (%) | 11 (17) | 14 (14) | 6 (10) |
| Fludarabine mono/combo, n (%) | 22 (33) | 36 (35) | 21 (33) |
| Cladribine monotherapy, n (%) | 5 (8) | 4 (4) | 6 (10) |
| RCHOP, n (%) | 1 (1) | 0 (0) | 2 (3) |
| RFC/RFCM, n (%) | 2 (3) | 10 (10) | 5 (8) |
| Others, n (%) | 4 (6) | 9 (9) | 9 (14) |

Follow-up from frontline therapy (mo), median (range) | 49 (4-150) | 34 (3-158) | 28 (4-143) | .056 |

Follow-up from CLL diagnosis (mo), median (range) | 101 (3-314) | 87 (4-463) | 86 (4-277) | .313 |

Abbreviations: FISH, fluorescent in-situ hybridization; B-CLL, B-cell chronic lymphocytic leukaemia; IGHV, immunoglobulin heavy chain variable region; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; COP, cyclophosphamide, vincristine and prednisone; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; RFCM, rituximab, fludarabine, cyclophosphamide and mitoxantrone; RFC, rituximab, fludarabine and cyclophosphamide.
FIGURE LEGENDS

Fig. 1. (A) Progression-free survival according to the A471V polymorphism in patients who required CLL-specific therapy and had a homozygous P224P (CC) genotype (P = 0.024). (B) Progression-free survival according to the A471V polymorphism in patients who required CLL-specific therapy, and had a homozygous P224P (CC) genotype and mutated IGHV (P = 0.028).